New Phase 2a data show the oral IPF therapy GRI-0621 modulates immune cell activity in adults with idiopathic pulmonary ...

Columnist Kylene Henderson is starting the year by focusing on progress and wellness, even if it means only small changes.

Columnist Ann Reynoso may have looked well during a recent holiday gathering, but living with PF meant she was battling ...

The gut bacteria B. adolescentis eased lung scarring in a pulmonary fibrosis mouse model, showing potential as a preventive ...

Columnist Sam Kirton explores what options are available to help IPF patients meet the costs of their medical care and medications.

Time felt like it was moving in slow motion for columnist Samuel Kirton after his IPF diagnosis. A lung transplant changed everything.

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

Building on positive Phase 2 data, Puretech Health plans to launch a Phase 3 trial in the coming months to further test its experimental oral therapy deupirfenidone (LYT-100) in people with idiopathic ...